EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 55c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Join SI Premium – FREE
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 EPS of ($1.16), $0.55 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.4 million.
For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oscar Health Inc. (OSCR) Tops Q3 EPS by 63c ; Offers Guidance
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
- EPAM Systems (EPAM) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
